BioPharma Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 9

1. ludwig mack 6 juni 2007 15:14

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   quote:

   DieGroeneGigant schreef:

   nu verkopen ? wat een onzin. gaat in juni nog naar de 6 en dan weer terug naar 2. let ook op voor al die warrants die executed worden.
   

   kun je daar op verder gaan ? bij welke prijs worden ze geplaatst; verschillende prijzen en aantallen toch ? maar interessant genoeg om inderdaad rekening mee te houden. het betekent niet dat ze meteen daarna op de markt komen toch ? dus zo makkelijk is het niet, maar wel overwegen. een idee ?
   dank en groet
2. ludwig mack 6 juni 2007 15:15

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   quote:

   SkySpam1 schreef:

   [quote=geldmaker72]
   
   Als je me gelooft skyspam!,dan moet je ze als de kans er nog is morgen allemaal verkopen en direkt AVNR kopen als ie nog niet omhoog geschoten is.Het is duidelijk dat die wel eens over de kop kan gaan van de week.
   [/quote]
   
   
   Ik zou wel echt van m'n voetstuk gaan en me zodanig tot bij de grond verlagen, moest ik op uw geroep ingaan.
   Laat me zeggen dat ik uw ~ strategie ~ al een tijdje doorheb.
   En niet zomaar op loos geschreeuw van iemand inga.
   Heb me daarvoor al véél te lang verdiept in GTCb, ik mag het niet gedroomd hebben eerstkomend te verkopen.
   Ik weet waarom het draait, alleen zitten er al maandelang manipulators te klooien.
   
   Ben je gek, het is dood of de gladiolen!!!!!
   Ooit wordt het beter!
   
   
   

   met jou wil ik later wel een borrel drinken ! je toon bevalt me wel :)
3. ludwig mack 6 juni 2007 15:15

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   quote:

   wous_ schreef:

   [quote=quert12]
   En dit gaat door en door en door, jarenlang. Wat een hopeloos aandeel en wat een sneue believers !!!
   [/quote]
   
   ik verkoop geen stukje, mij krijgen ze niet gek,
   mijn vertrouwen erin blijft staan als een rots,
   2010 ; 6 a 8 dollar
   

   ook met jou !
4. [verwijderd] 6 juni 2007 15:18

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ach een gezamelijke $10.00 borrel zou niet verkeerd zijn.
   
   Misschien doen de mannen van Pharming ook mee..
   
   Een gezellige transgene borrelavond.
5. [verwijderd] 6 juni 2007 15:40

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   ludwig mack schreef:

   [quote=DieGroeneGigant]
   nu verkopen ? wat een onzin. gaat in juni nog naar de 6 en dan weer terug naar 2. let ook op voor al die warrants die executed worden.
   [/quote]
   
   kun je daar op verder gaan ? bij welke prijs worden ze geplaatst; verschillende prijzen en aantallen toch ? maar interessant genoeg om inderdaad rekening mee te houden. het betekent niet dat ze meteen daarna op de markt komen toch ? dus zo makkelijk is het niet, maar wel overwegen. een idee ?
   dank en groet
   

   Deze discussie hebben we allang breed gevoerd op dit forum en verwijs je naar eerdere postings.
6. [verwijderd] 6 juni 2007 15:41

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   ramon72 schreef:

   Ach een gezamelijke $10.00 borrel zou niet verkeerd zijn.
   
   Misschien doen de mannen van Pharming ook mee..
   
   Een gezellige transgene borrelavond.
   

   Toch geen geitenmelk met een schuimkraag ?
7. ludwig mack 6 juni 2007 15:43

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   1,20 ( 15:33 ) 0,01 / 0,84%
   
   
   Laatste volume 100
   Volume 8.661
   
   Slot 1,19 5-6-2007
   Open 1,19 15:33
   Hoog 1,20 15:33
   Laag 1,19 15:33
   
8. ludwig mack 6 juni 2007 15:45

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 10 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   quote:

   DieGroeneGigant schreef:

   [quote=ludwig mack]
   [quote=DieGroeneGigant]
   nu verkopen ? wat een onzin. gaat in juni nog naar de 6 en dan weer terug naar 2. let ook op voor al die warrants die executed worden.
   [/quote]
   
   kun je daar op verder gaan ? bij welke prijs worden ze geplaatst; verschillende prijzen en aantallen toch ? maar interessant genoeg om inderdaad rekening mee te houden. het betekent niet dat ze meteen daarna op de markt komen toch ? dus zo makkelijk is het niet, maar wel overwegen. een idee ?
   dank en groet
   [/quote]
   
   Deze discussie hebben we allang breed gevoerd op dit forum en verwijs je naar eerdere postings.
   

   leuk !
   volgens mij nooit exacte berekeningen, maar laat dan maar. we zien wel hoe het straks afloopt. kan tegenvallen bij een stijging als er erg veel in de laat volloopt.
9. [verwijderd] 6 juni 2007 17:27

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hier alles nog zijn gangetje zie ik -))
   
   Nog eventjes vol houden.
   
   Grtz CV
10. [verwijderd] 6 juni 2007 17:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    CapraVacca schreef:

    Hier alles nog zijn gangetje zie ik -))
    
    Nog eventjes vol houden.
    
    Grtz CV
    

    Ha die CV, das lang geleden,
    alles goed met het mooie karretje?!
12. [verwijderd] 6 juni 2007 17:47

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    kun je daar op verder gaan ? bij welke prijs worden ze geplaatst; verschillende prijzen en aantallen toch ? maar interessant genoeg om inderdaad rekening mee te houden. het betekent niet dat ze meteen daarna op de markt komen toch ? dus zo makkelijk is het niet, maar wel overwegen. een idee ?
    dank en groet
    

    Nogal moeilijk om het bos door de bomen te blijven zien!!
    
    www.secinfo.com/d14D5a.v4Hsb.htm
    
    Genzyme’s significant ownership interest in us could give it significant influence over matters
    requiring stockholder approval.
    Genzyme is our largest single stockholder, beneficially owning 5,443,243 shares or 16.8% of our
    outstanding common stock at December 12, 2003, assuming the exercise of its 518,324 currently
    exercisable common stock purchase warrants with exercise prices ranging from $6.30 to $2.84. As a
    16.8% shareholder, Genzyme’s ownership interest could give it significant influence if it were to oppose
    matters requiring our stockholders’ approval, including electing directors, adopting or amending
    provisions of our charter or by-laws and approving or preventing some mergers or similar transactions,
    such as a sale of substantially all of our assets, or transactions that could give our stockholders the
    opportunity to realize a premium over the market price of their shares.
    www.gtc-bio.com/investorinfo/s3122303...
    
    Ben nogal moe en zelfs wat lui om verder te zoeken, misschien in het weekend.
    
    Maar GG, $zes zal (heel) moeilijk worden, maar goed,
    zeg nooit, nooit!!
13. [verwijderd] 6 juni 2007 19:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Genzyme is our largest single stockholder, beneficially owning 5,443,243 shares or 16.8% of our
    outstanding common stock at December 12, 2003
    
    Geschiedenis schrijven is leuk maar wat mot je er mee!
    
    Vriendelijke groet,
    
14. [verwijderd] 6 juni 2007 19:35

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    Genzyme is our largest single stockholder, beneficially owning 5,443,243 shares or 16.8% of our
    outstanding common stock at December 12, 2003
    
    Geschiedenis schrijven is leuk maar wat mot je er mee!
    
    Vriendelijke groet,
    
    

    Het ging hem over de warrants wish,
    zie voorafgaande discussie.
15. [verwijderd] 6 juni 2007 19:47

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Nu dit is wat ik kan vinden word vervolgd!
    
    GTC BIOTHERAPEUTICS ANNOUNCES PRIVATE PLACEMENT OF COMMON STOCK AND WARRANTS
    
    FRAMINGHAM, MA - July 30, 2003 -- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that it has entered into definitive agreements with certain institutional and accredited investors for a private placement of Common Stock and Common Stock Purchase Warrants. GTC has agreed to sell an aggregate of approximately 3.63 million shares of Common Stock at $2.55 per share. The investors will also receive warrants to purchase an aggregate of approximately 0.9 million shares of GTC's Common Stock at an exercise price of $3.30 per share.
    
    SG Cowen Securities Corporation acted as exclusive placement agent for the securities sold in this transaction. The proceeds of the financing are expected to be used for general corporate purposes, including funding GTC's ongoing clinical trials and operations.
    
    This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from registration requirements. GTC has agreed to file a resale registration statement on Form S-3 within 30 days after the closing of the transaction for purposes of registering the shares of Common Stock, as well as the shares of Common Stock underlying the warrants, acquired by these investors.
    
    GTC Biotherapeutics is the leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC has more than a dozen programs in development, including its internal proprietary products, one of which is in clinical trials. GTC has begun a clinical efficacy study in Europe with its lead internal program, recombinant human antithrombin III (rhATIII), a human blood plasma protein. In addition to the rhATIII program, GTC is developing a recombinant human serum albumin and a malaria vaccine. In GTC's external programs, GTC's technology is used to develop transgenic production of the partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional bioreactor systems. GTC's external program collaborations are developing transgenic versions of products such as monoclonal antibodies and immunoglobulin fusion proteins for conditions such as rheumatoid arthritis, HIV/AIDS and cancer. Additional information is available on the GTC web
16. [verwijderd] 6 juni 2007 19:48

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Nu dit is wat ik kan vinden word vervolgd!
    
    GTC BIOTHERAPEUTICS ANNOUNCES PRIVATE PLACEMENT OF COMMON STOCK AND WARRANTS
    
    FRAMINGHAM, MA - August 8, 2005 -- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that it has entered into definitive agreements with certain institutional investors for a private placement of Common Stock and Common Stock Purchase Warrants. GTC has agreed to sell an aggregate of approximately 4.57 million shares of Common Stock at $1.75 per share. The investors will also receive 5-year warrants to purchase an aggregate of approximately 1.8 million additional shares of GTC's Common Stock at an exercise price of $2.68 per share.
    
    Rodman & Renshaw, LLC acted as exclusive placement agent for the securities sold in this transaction. The proceeds of the financing are expected to be used for general corporate purposes, including funding GTC's ongoing clinical trial activities and preparations for commercialization of ATryn®, pending review of the Market Authorization Application (MAA) for ATryn® by the European Medicines Agency (EMEA).
    
    This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from registration requirements. GTC has agreed to file a resale registration statement on Form S-3 within 20 days after the closing of the transaction for purposes of registering the shares of Common Stock, as well as the shares of Common Stock underlying the warrants, acquired by these investors.
    
    About GTC Biotherapeutics
    GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. An MAA is under review by the EMEA for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the
17. [verwijderd] 6 juni 2007 19:49

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    QUESTIONS BY INVESTORS
    
    The following is a general list of questions you may have regarding GTC Biotherapeutics. For further information, please contact GTC Biotherapeutics Investor Relations at (508)-370-5374.
    
    1. What is the relationship between GTC Biotherapeutics and Genzyme Corporation?
    
    GTC Biotherapeutics is a stand-alone public company traded on the Nasdaq National Market System. In July 1993, Genzyme Transgenics was organized as a separate business, distinct from Genzyme Corporation, in order to fully realize the potential value of producing therapeutic proteins in the milk of transgenic animals. On June 3, 2002, Genzyme Transgenics became GTC Biotherapeutics in order to bring clarity to its identity and independence while highlighting the familiar initials by which it was already known.
    
    As of April 6, 2005, Genzyme Corporation owns approximately 4.9 million shares of GTC Biotherapeutics common stock with warrants exercisable for approximately 370,000 additional shares, and is GTC’s largest minority shareholder.
18. [verwijderd] 6 juni 2007 19:50

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ATryn® MARKET AUTHORIZATION TRANSFERRED TO LEO PHARMA A/S
    
    FRAMINGHAM, MA - December 8, 2005 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has obtained agreements from select institutional investors to purchase approximately 9.1 million shares of GTC's common stock at a price of $1.78 per share, the closing bid price for the common stock immediately before entering into the binding agreements for the transaction. Under the terms of the financing, GTC will also issue 5-year warrants to purchase an aggregate of approximately 3.6 million additional shares of GTC's common stock at an exercise price of $2.05 per share. At the closing, investors in the financing will pay an additional purchase price equal to $0.125 per each share issuable upon exercise of the warrants. The closing of the offering is expected to take place on December 13, 2005, subject to the satisfaction of customary closing conditions.
    
    The shares and warrants are being offered under a shelf registration statement previously filed with the Securities and Exchange Commission, which was declared effective on November 14, 2005. SG Cowen & Co., LLC served as lead placement agent for the offering and Rodman & Renshaw, LLC acted as co-agent for the transaction.
    
    GTC estimates gross proceeds from the financing will be approximately $16.7 million. The net proceeds of the financing will be used for general corporate purposes.
    
    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the prospectus and the prospectus supplement can be obtained from SG Cowen & Co., LLC, 1221 Avenue of the Americas, New York, NY 10020, fax +1 (646) 562-1269.
19. [verwijderd] 6 juni 2007 19:51

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC BIOTHERAPEUTICS TO RAISE $17.8 MILLION IN REGISTERED DIRECT OFFERING
    
    FRAMINGHAM, MA - July 18, 2006 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has obtained agreements from new and existing institutional investors, including William Harris Investors, Inc., to purchase 12 million shares of GTC's common stock at a price of $1.38 per share, the closing bid price for the common stock immediately before entering into the binding agreements for the transaction. Under the terms of the financing, GTC will also issue 10-year warrants to purchase an aggregate of 7.8 million additional shares of GTC's common stock at an exercise price of $1.4145 per share. At the closing, investors in the financing will pay an additional purchase price equal to $0.125 for each share issuable upon exercise of the warrants. The closing of the offering is expected to take place on July 21, 2006, subject to the satisfaction of customary closing conditions.
    
    The shares and warrants are being offered under a shelf registration statement previously filed with the Securities and Exchange Commission. C.E. Unterberg, Towbin served as lead placement agent for the offering. Oppenheimer & Co. and Rodman & Renshaw, LLC acted as co-agents for the transaction.
    
    GTC estimates gross proceeds from the financing will be approximately $17.5 million. The net proceeds of the financing will be used for general corporate purposes.
    
    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the prospectus and the prospectus supplement can be obtained from C.E. Unterberg, Towbin, 350 Madison Avenue, New York, NY 10017, fax +1 (212) 389-8880.
    
    About GTC Biotherapeutics
    GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC's lead program is ATryn®, its recombinant form of human antithrombin. The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding GTC application for the use of ATryn® in patients with a hereditary antithrombin deficiency undergoing surgical procedures. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.
    
    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including the amount of proceeds expected to be received from the planned closing of the public offering. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the risks and uncertainties inherent in satisfying the conditions to the closing of such a transaction. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
20. [verwijderd] 6 juni 2007 19:54

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Kan je er iets mee sky ?
    
    Met dit knip en plak werk.
    
    Succes
    
    Groet,
    
    
21. ludwig mack 6 juni 2007 20:51

    auteur info

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    dit is knippen en plakken:
    
    The investors will also receive warrants to purchase an aggregate of approximately 0.9 million shares of GTC's Common Stock at an exercise price of $3.30 per share.
    
    The investors will also receive 5-year warrants to purchase an aggregate of approximately 1.8 million additional shares of GTC's Common Stock at an exercise price of $2.68 per share.
    
    As of April 6, 2005, Genzyme Corporation owns approximately 4.9 million shares of GTC Biotherapeutics common stock with warrants exercisable for approximately 370,000 additional shares, and is GTC’s largest minority shareholder.
    
    Under the terms of the financing, GTC will also issue 10-year warrants to purchase an aggregate of 7.8 million additional shares of GTC's common stock at an exercise price of $1.4145 per share. At the closing, investors in the financing will pay an additional purchase price equal to $0.125 for each share issuable upon exercise of the warrants. The closing of the offering is expected to take place on July 21, 2006, subject to the satisfaction of customary closing conditions.
    
    Under the terms of the financing, GTC will also issue 5-year warrants to purchase an aggregate of approximately 3.6 million additional shares of GTC's common stock at an exercise price of $2.05 per share. At the closing, investors in the financing will pay an additional purchase price equal to $0.125 per each share issuable upon exercise of the warrants. The closing of the offering is expected to take place on December 13, 2005, subject to the satisfaction of customary closing conditions
    
    volgens mij komen daar dan de warrrants van de denen en fransen nog bij; de uitoefenprijs is verschillend, maar wat hier boven betreft min. 1,40 en max. 3,30 dollar, snel gekeken, met sub.totaal van 14.47 mln warrants. nog een hele hoop. zijn er al warrants meteen geeffectueerd destijds, dan moeten die er weer af ?
    gr